InvestorsHub Logo

stockinvestor56

08/29/16 10:57 AM

#896 RE: cjstocksup #895

CJ, that is a regurgitation of a previous PR. And now you can't access that article on Yahoo. What's going on??

crudeoil24

09/13/16 10:00 AM

#924 RE: cjstocksup #895

"These results are astonishingly good. Other drug treatments and controls tested in similar studies have been associated with a prostate cancer incidence 10 times higher than the results reported by Nymox for fexapotide. This is truly good news. The data strongly indicate that in addition to benefit for BPH symptoms, fexapotide will also help to prevent cancer in these patients," said Dr. Ronald Tutrone, one of the Principal Investigators in the Nymox Fexapotide Prostate Cancer and BPH studies. Dr. Tutrone is Chief of the Division of Urology, Greater Baltimore Medical Center; Medical Director of Chesapeake Urology Research Associates and Chairman of the William E. Kalhert Endowment for Urological Research.